Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years, ...

Popular weight loss drugs such as Wegovy and Zepbound have shown incredible success in clinical trials. But in the real world ...